This is a routine operational update with no material impact on valuation. Monitor for the interim analysis after 144 patient deaths, which is the next major catalyst. The Nature Medicine mention adds credibility but does not change the binary risk profile of a Phase 3 readout.
Price Chart
Executive Summary
BriaCell announced the addition of Penn Medicine's Abramson Cancer Center as a clinical trial site for its pivotal Phase 3 Bria-ABC study evaluating Bria-IMT in combination with an immune checkpoint inhibitor for advanced breast cancer. This is a routine operational update that expands patient access but does not provide new efficacy or safety data, making it a low-impact event for a micro-cap biotech.
Key Facts
- Penn Medicine's Abramson Cancer Center added as a clinical trial site for the Phase 3 Bria-ABC study.
- Phase 3 study evaluates Bria-IMT plus immune checkpoint inhibitor vs. physician's choice in advanced metastatic breast cancer.
- Interim analysis will be conducted after 144 patient deaths (overall survival primary endpoint).
- Bria-IMT regimen has FDA Fast Track designation.
- Other recently activated sites include Indiana University, UVA, Baptist Health South Florida, and SCRI Oncology Partners.
- The study was independently included in Nature Medicine's 'Eleven clinical trials that will shape medicine in 2026'.
Financial Impact
No financial data disclosed; clinical-stage company with no approved products or revenue.
Risk Factors
- Phase 3 trial may fail to meet overall survival endpoint.
- Micro-cap biotech with high cash burn and potential need for dilutive financing.
- No revenue or approved products; stock is highly speculative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers